Abstracts tagged "Comorbidity"

Abstract Number: 0476 • ACR Convergence 2025
Impact of Comorbidity Burden on the Efficacy of, a Direct Interleukin 6 Inhibitor, Olokizumab: Real World Evidence
Maxim Korolev¹, Alexander Dubikov², Daria Bukhanova³, Alina Egorova³, Eugenyi Alekseev⁴, Sofia Kuzkina⁵ and Mikhail Samsonov³, ¹Research Institute of Clinical and Experimental Lymрhology – Branch of the Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences, Novosibirsk, Russia, ²Rheumatology clinic of Professor Dubikov A.I., Vladivostok, Russia, ³R-Pharm JSC, Moscow, Russia, ⁴"R-Pharm", JSC, Moscow, Russia, ⁵R-Pharm, Moscow, Russia
Background/Purpose: Comorbidities may affect the efficacy of bDMARDs in rheumatoid arthritis (RA). Post-hoc analysis of the randomized clinical trial (RCT) data shows that the efficacy…
Abstract Number: 1554 • ACR Convergence 2025
Demographic, Clinical, and Mortality Trends in Scleroderma Patients with Gastric Antral Vascular Ectasia (GAVE): A National Inpatient Analysis
Akanksha Sharma¹, Veera Durga Vaishnavi Kurra² and Neev Mehta³, ¹UPMC Mercy hospital, Pittsburgh, PA, Pittsburgh, PA, ²University of Oklahoma Health Sciences Center, Oklahoma City, OK, ³Lahey Hospital and Medical Center, Burlington, MA
Background/Purpose: Gastric antral vascular ectasia (GAVE), commonly known as “watermelon stomach,” is a rare but potentially severe gastrointestinal manifestation in systemic sclerosis (SSc). Despite its…
Abstract Number: 2252 • ACR Convergence 2025
Association between frailty and survival among older adults with rheumatoid arthritis and lung cancer
Michelle Nguyen¹, Aaron Baraff², Alexander Peterson², Alexandra Schmidt², Katherine Wysham³, Aliyah Pabani⁴, Carolyn Presley⁵, Nicholas Smith¹, Shelly Gray¹, Jose Garcia⁶, Ariela Orkaby⁷ and Namrata Singh¹, ¹University of Washington, Seattle, WA, ²VA Puget Sound Health Care System, Seattle, WA, ³VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ⁴Johns Hopkins, Washington, DC, ⁵Ohio State University Medical Center, Columbus, ⁶VA Puget Sound Health Care System, VA GRECC, and University of Washington, Seattle, WA, ⁷VA Boston Healthcare System & Division of Aging, Brigham and Women’s Hospital, Harvard Medical School & VA Geriatrics Research Education and Clinical Center, Boston, MA
Background/Purpose: Individuals with rheumatoid arthritis (RA) have a higher prevalence of frailty, even at younger ages, compared to the general population1. Among persons with lung…
Abstract Number: 0528 • ACR Convergence 2025
Apolipoprotein A1 and B Levels Indicate Specific Lipid Changes In Early Treatment Naïve Psoriatic Arthritis and Correlate With 1-year Disease Activity
Alla Ishchenko¹, Margot Van Mechelen², Barbara Neerinkx¹, Patrick Verschueren³, Rik Lories¹ and Kurt de Vlam⁴, ¹KU Leuven, Leuven, Belgium, ²UZA Antwerp, Antwerp, Belgium, ³Rheumatology, University Hospital Leuven and Skeletal Biology and Engineering Research Centre, KU Leuven, Leuven, Belgium, ⁴KU Leuven, UZ Gasthuisberg, Leuven, Belgium
Background/Purpose: Psoriatic arthritis (PsA) is associated with increased cardiovascular risk and a pro-atherogenic lipid profile. We hypothesize that alterations in lipid metabolism combined with systemic…
Abstract Number: 1636 • ACR Convergence 2025
The Impact of Arthritis on Self-Management Activities of West Virginia Adults with Type 2 Diabetes During the COVID-19 Pandemic
Dina Maruca¹, Teresa Brady², Gerald Hobbs, Jr.¹ and Ranjita Misra¹, ¹West Virginia University, Morgantown, WV, ²Clarity Consulting and Communications, Atlanta, GA
Background/Purpose: One-third of adults with Type 2 diabetes (T2D) also have arthritis. West Virginia (WV), the 3rd most rural US state, has the highest prevalence…
Abstract Number: 2266 • ACR Convergence 2025
Impact of Rheumatoid Arthritis Therapeutic Classes on Risk of All-Cause Mortality and All-Cause Cancer: A Population-Based Cohort Study
Mohammad Movahedi¹, Angela Cesta¹, Sibel Aydin², Pooneh Akhavan³, Tetyana Kendzerska⁴, Claire Bombardier¹ and Bindee Kuriya⁵, ¹Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ²Department of Medicine, University of Ottawa, The Ottawa Hospital Research Institute, Ottawa, ON, Canada, ³self-employed, Toronto, ON, Canada, ⁴Ottawa Hospital Research Institute, Mississuaga, ON, Canada, ⁵University of Toronto - Toronto, Toronto, ON, Canada
Background/Purpose: Observational studies on RA therapeutic classes have shown conflicting results on their impact on mortality and cancer. When analyzing long-term outcomes, it is essential…
Abstract Number: 0546 • ACR Convergence 2025
Multimorbidity clusters in psoriatic arthritis, psoriasis, and axial spondyloarthritis and their association with healthcare utilization: A population-based study
Paras Karmacharya¹, Dilli Poudel², Daniel Shin³, Robert Fitzsimmons³, Leslie Crofford⁴ and Alexis Ogdie⁵, ¹Vanderbilt University, Nashville, TN, Hermitage, TN, ²Vanderbilt University Medical Center, Nashville, TN, ³University of Pennsylvania, Philadelphia, ⁴Vanderbilt University Medical Center, Melbourne, AR, ⁵University of Pennsylvania, Philadelphia, PA
Background/Purpose: Multimorbidity (≥ 2 chronic conditions) is common in inflammatory diseases such as psoriatic arthritis (PsA), psoriasis (PsO), and axial spondyloarthritis (AxSpA), increasing patient burden…
Abstract Number: 1712 • ACR Convergence 2025
Reduced Cardiometabolic Burden and Inflammation in Patients with Psoriatic Arthritis Cared for in a Multi-Disciplinary, Combined Psoriasis-Psoriatic Arthritis Center
Rebecca Haberman¹, Nicolas Coudray², Xu Han², Morgan Grams², Eric Oermann², Aristotelis Tsirigos² and Jose Scher³, ¹NYU Langone Health, New York, NY, ²NYU Grossman School of Medicine, New York, ³New York University School of Medicine, New York, NY
Background/Purpose: Psoriatic arthritis (PsA) is a chronic, systemic inflammatory disease that affects both the skin and musculoskeletal system and is frequently associated with a heightened…
Abstract Number: 2292 • ACR Convergence 2025
Safety and Humoral Response to Recombinant Herpes Zoster Vaccine in immunosuppressed Sjögren’s Disease Patients: Results From a Double-Blinded Placebo-Controlled Study
Sandra G Pasoto¹, Talita Ribeiro², Nadia Emi Aikawa³, Ana C Medeiros-Ribeiro¹, Bruno Borges², Andre Franco⁴, Henrique Silva², Eloisa Bonfa⁵ and Clovis Artur Silva⁶, ¹Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, Brazil, ²Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, Brazil, ³Rheumatology Division and Pediatric Rheumatology Unit, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, São Paulo, Brazil, ⁴Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, Sao Paulo, Brazil, ⁵Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, São Paulo, Brazil, ⁶University of São Paulo, São Paulo, São Paulo, Brazil
Background/Purpose: Immunosuppressed Sjögren’s disease (SjD) patients are at increased risk of herpes zoster (HZ). Despite this vulnerability, data on safety and immunogenicity of the recombinant…
Abstract Number: 0579 • ACR Convergence 2025
Characteristics and Treatment Patterns among Patients with Psoriatic Arthritis in the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry Initiating a Third or Higher Line of Biologic or Targeted Disease-Modifying Antirheumatic Drug Therapy
Philip J. Mease¹, Nicole Middaugh², Yolanda Muñoz Maldonado², Chao Song³, Melissa Eliot², Robert Low³ and Alexis Ogdie⁴, ¹Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ²CorEvitas, LLC, Waltham, MA, ³UCB, Smyrna, GA, ⁴University of Pennsylvania, Philadelphia, PA
Background/Purpose: Psoriatic arthritis (PsA) is a heterogeneous chronic inflammatory disease affecting the joints, skin, and other regions of the body. It impacts up to 36%…
Abstract Number: 1883 • ACR Convergence 2025
Temporal Patterns of Cardiometabolic Comorbidities Before and After Psoriatic Arthritis Diagnosis: A Nationwide Retrospective Study from Poland.
Batko Bogdan¹, Mateusz Szeląg², Krzysztof Batko³, Magdalena Krajewska-Włodarczyk⁴, Zbigniew Żuber⁵, Marcin Stajszczyk⁶, Brygida Kwiatkowska⁷ and Tomasz Guzik⁸, ¹Department of Rheumatology and Immunology, Faculty of Medicine and Health Sciences, Andrzej Frycz Modrzewski University, Krakow, Poland, Kraków, Poland, ²Ministry of Health, Warsaw, Poland, ³Department of Dermatology, University Hospital in Krakow, Poland, Krakow, Poland, ⁴University of Warmia & Mazury, Olsztyn, Poland, ⁵Department of Pediatrics, Faculty of Medicine and Health Sciences, Andrzej Frycz Modrzewski University, Krakow, Poland, Krakow, Poland, ⁶Department of Rheumatology and Autoimmune Diseases, Silesian Center for Rheumatology, Orthopedics and Rehabilitation, Ustroń, Poland, Ustron, Poland, ⁷Clinic of Early Arthritis, National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland, Warsaw, Poland, ⁸BHF Centre for Research Excellence, Centre for Cardiovascular Sciences, The University of Edin-burgh, Edinburgh, UK, Edinburgh, United Kingdom
Background/Purpose: While the association between psoriatic arthritis (PsA) and cardiometabolic disorders is established, the temporal sequence and progression of these comorbidities remain poorly characterized. To…
Abstract Number: 2330 • ACR Convergence 2025
Correlation of Comorbidities with Psoriatic Arthritis Duration in Elderly Veterans – A Retrospective Cohort Study
Siba Raychaudhuri¹, Smriti K Raychaudhuri², Jessica A. Walsh³, Gail Kerr⁴, Maureen Dubreuil⁵, Bernard Ng⁶, Elizabeth Chang⁷, Andreas Reimold⁸ and Liron Caplan⁹, ¹UC Davis, School of Medicine/ VA Medical Center, Sacramento, Davis, CA, ²Sacramento VA Medical Center, Davis, CA, ³Division of Rheumatology, Salt Lake City Veterans Affairs Health and University of Utah Health, Salt Lake City, UT, ⁴Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ⁵Boston University School of Medicine, Milton, MA, ⁶Veteran Affairs, Seattle, WA, ⁷PVAHCS, Phoenix, AZ, ⁸Dallas VA Medical Center, Dallas, TX, ⁹Rocky Mountain Regional VAMC, Aurora, CO
Background/Purpose: Psoriasis and psoriatic arthritis (PsA) are associated with several comorbid conditions including metabolic disease, chronic kidney disease as well as mental health disorders. However,…
Abstract Number: 0077 • ACR Convergence 2025
Transformer-based multi-omics study identifies important role of glycine, serine and threonine metabolism pathway in rheumatoid arthritis complicated by anemia
Fanxin zeng¹, Jianxin Huang², Yuanli Wei³, Dongmei Wang³, Jianghua Chen⁴, Congcong Jian¹, Xiaoting Zhu⁵, Shilin Li⁵, Jie Zhang⁵, Tingting Wang³, Caizhen Liu⁶, Lingli Wei³, Jing Gao³, Jing Zhu⁷, Qinghua Zou⁸ and Jianhong Wu³, ¹Departmant of Clinical Research Center, Sichuan Clinical Research Center for Medical Imaging, Dazhou Central Hospital; Medical School, Sichuan University of Arts and Sciences; School of Basic Medical Science, Chengdu University of Traditional Chinese Medicine, Dazhou, China (People's Republic), ²Institute of Basic Medicine and Forensic Medicine, North Sichuan Medical College, Nanchong, China (People's Republic), ³Department of Rheumatology and Immunology, Dazhou Central Hospital, Dazhou, China (People's Republic), ⁴Dazhou Vocational College of Chinese Medicine, Dazhou, China (People's Republic), ⁵Departmant of Clinical Research Center, Sichuan Clinical Research Center for Medical Imaging, Dazhou Central Hospital, Dazhou, China (People's Republic), ⁶Department of Rheumatology and Immunology, Dazhou Central Hospital, Dazhou, ⁷Department of Rheumatology and Immunology, Sichuan Provincial People's Hospital, Chengdu, China (People's Republic), ⁸Department of Rheumatology and Immunology, First Affiliated Hospital of Army Medical University, Chongqing, China (People's Republic)
Background/Purpose: Anemia is a prevalent hematologic complication of rheumatoid arthritis (RA) that exacerbates the disease process and severely impacts clinical performance and treatment strategies. We…
Abstract Number: 1017 • ACR Convergence 2025
Effectiveness of Recombinant Zoster Vaccine in Reducing Herpes Zoster Incidence and All-Cause Mortality Among Rheumatoid Arthritis Patients: A Retrospective Cohort Study of 21,046 Individuals from TriNetX U.S. Collaborative Network
James Wei¹, Shiow-Ing Wang² and Ying-Li Lin², ¹Chung Shan Medical University Hospital, Taichung, Taichung, Taiwan (Republic of China), ²Chung Shan Medical University Hospital; China Medical University, Taichung, Taiwan (Republic of China)
Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased risk of developing herpes zoster (HZ). This study aimed to assess the effectiveness of recombinant zoster…
Abstract Number: 1894 • ACR Convergence 2025
Opioid Use Disorder Among Patients with Rheumatic Conditions in the All of Us Research Program: A Descriptive Analysis
Jacob Riegler¹, Leah Santacroce², Karen H. Costenbader³ and Candace Feldman⁴, ¹Cambridge Health Alliance, Harvard Medical School, Somerville, MA, ²Brigham and Women's Hospital, Boston, MA, ³Harvard Medical School and Brigham and Women's Hospital, Boston, MA, ⁴Brigham and Women's Hospital/ Harvard Medical School, Boston
Background/Purpose: Opioid use disorder (OUD) is associated with high morbidity and mortality and in the U.S. in 2022, resulted in over 81,000 overdose deaths.1 However,…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].